The Membrane Attack Complex (MAC) is responsible for forming large β-barrel channels in the membranes of pathogens, such as gram-negative bacteria. Off-target MAC assembly on endogenous tissue is associated with inflammatory diseases and cancer. Accordingly, a human C5b-9 specific antibody, aE11, has been developed that detects a neoepitope exposed in C9 when it is incorporated into the C5b-9 complex, but not present in the plasma native C9. For nearly four decades aE11 has been routinely used to study complement, MAC-related inflammation, and pathophysiology. However, the identity of C9 neoepitope remains unknown. Here, we determined the cryo-EM structure of aE11 in complex with polyC9 at 3.2 Å resolution. The aE11 binding site is formed by two separate surfaces of the oligomeric C9 periphery and is therefore a discontinuous quaternary epitope. These surfaces are contributed by portions of the adjacent TSP1, LDLRA, and MACPF domains of two neighbouring C9 protomers. By substituting key antibody interacting residues to the murine orthologue, we validated the unusual binding modality of aE11. Furthermore, aE11 can recognise a partial epitope in purified monomeric C9 in vitro, albeit weakly. Taken together, our results reveal the structural basis for MAC recognition by aE11.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838529PMC
http://dx.doi.org/10.1038/s42003-023-04431-yDOI Listing

Publication Analysis

Top Keywords

membrane attack
8
attack complex
8
ae11
7
neoepitope complement
4
complement c5b-9
4
c5b-9 membrane
4
complex
4
complex formed
4
formed proximity
4
proximity adjacent
4

Similar Publications

Unlabelled: The spirochete causes Lyme disease. In some patients, an excessive, dysregulated proinflammatory immune response can develop in joints leading to persistent arthritis. In such patients, persistence of antigenic peptidoglycan (PG ) fragments within joint tissues may contribute to the immunopatho-genesis, even after appropriate antibiotic treatment.

View Article and Find Full Text PDF

A toolbox for early detection of glass delamination in vials.

Int J Pharm

January 2025

Drug Product and Device Technologies, BioMarin Pharmaceutical, Inc, Novato, CA 94949, USA.

Glass delamination is a gradual process that may not become apparent until late in storage. Over the past three decades, it has been a leading cause of drug product recalls due to glass particulate contamination. The appearance of glass particles in the solution marks the final stage of glass delamination.

View Article and Find Full Text PDF

Optimization of a micro-scale air-liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2.

Respir Res

January 2025

Department of Pediatrics, David Geffen School of Medicine, UCLA Children's Discovery and Innovation Institute, Mattel Children's Hospital UCLA, UCLA, Los Angeles, CA, 90095, USA.

Background: Many respiratory viruses attack the airway epithelium and cause a wide spectrum of diseases for which we have limited therapies. To date, a few primary human stem cell-based models of the proximal airway have been reported for drug discovery but scaling them up to a higher throughput platform remains a significant challenge. As a result, most of the drug screening assays for respiratory viruses are performed on commercial cell line-based 2D cultures that provide limited translational ability.

View Article and Find Full Text PDF

Vacuolar myopathy with monoclonal gammopathy and stiffness (VAMMGAS).

Eur J Neurol

January 2025

Groupe Hospitalier Pitié-Salpêtrière, Institut de Myologie, AP-HP, Sorbonne Université, Paris, France.

Background: Monoclonal gammopathy (MG) has been reported in association with numerous neurological disorders but the spectrum of MG-associated myopathies remains poorly described.

Objective: To report a newly acquired myopathy associated with MG.

Methods: Three adult patients with the same phenotype from two French referral centers were prospectively analyzed.

View Article and Find Full Text PDF

Macrophage membrane-camouflaged pure-drug nanomedicine for synergistic chemo- and interstitial photodynamic therapy against glioblastoma.

Acta Biomater

January 2025

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address:

Glioblastoma (GBM) persists as a highly fatal malignancy, with current clinical treatments showing minimal progress over years. Interstitial photodynamic therapy (iPDT) holds promise due to its minimally invasive nature and low toxicity but is impeded by poor photosensitizer penetration and inadequate GBM targeting. Here, we developed a biomimetic pure-drug nanomedicine (MM@CT), which co-assembles the photosensitizer chlorin e6 (Ce6) and the first-line chemotherapeutic drug (temozolomide, TMZ) for GBM, then camouflaged with macrophage membranes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!